Last reviewed · How we verify

Prednisone, ciclosporin and mycophenolate mofetil

Beijing Friendship Hospital · FDA-approved active Small molecule Quality 5/100

Prednisone, ciclosporin and mycophenolate mofetil is a Small molecule drug developed by Beijing Friendship Hospital. It is currently FDA-approved.

Prednisone, ciclosporin, and mycophenolate mofetil are marketed drugs developed by Beijing Friendship Hospital, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and broad therapeutic applications. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic namePrednisone, ciclosporin and mycophenolate mofetil
SponsorBeijing Friendship Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prednisone, ciclosporin and mycophenolate mofetil

What is Prednisone, ciclosporin and mycophenolate mofetil?

Prednisone, ciclosporin and mycophenolate mofetil is a Small molecule drug developed by Beijing Friendship Hospital.

Who makes Prednisone, ciclosporin and mycophenolate mofetil?

Prednisone, ciclosporin and mycophenolate mofetil is developed and marketed by Beijing Friendship Hospital (see full Beijing Friendship Hospital pipeline at /company/beijing-friendship-hospital).

What development phase is Prednisone, ciclosporin and mycophenolate mofetil in?

Prednisone, ciclosporin and mycophenolate mofetil is FDA-approved (marketed).

Related